Facebook tracking pixel

Coming Soon

S10.AI's Next-Generation Telehealth Platform

A04.72
ICD-10-CM
Clostridium difficile

Learn about Clostridium difficile (C. diff) diagnosis, including clinical documentation requirements, ICD-10-CM coding for C. difficile infection, and healthcare best practices for managing Clostridioides difficile. This resource provides information on C. diff testing and treatment to support accurate medical coding and improved patient care.

Also known as

C. diff
Clostridioides difficile
C. difficile infection
+1 more

Diagnosis Snapshot

Key Facts
  • Definition : Bacterial infection causing inflammation of the colon.
  • Clinical Signs : Watery diarrhea, abdominal pain, fever. Severe cases can lead to toxic megacolon.
  • Common Settings : Hospitals, nursing homes, and after antibiotic use.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC A04.72 Coding
A04.7

Enterocolitis due to Clostridium difficile

Inflammation of the small and large intestines caused by C. diff.

A04

Other bacterial intestinal infections

Infections of the intestines caused by bacteria other than specified types.

R19.7

Diarrhea, unspecified

Loose, watery stools without a specified cause, which can be a symptom of C. diff.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the C. difficile infection confirmed?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Bacterial infection causing diarrhea and colitis.
Inflammation of the colon, not due to C. difficile.
Antibiotic-associated diarrhea, C. difficile negative.

Documentation Best Practices

Documentation Checklist
  • Document C. difficile toxin assay results.
  • Specify CDI onset: hospital-acquired or community-acquired.
  • Detail symptoms: diarrhea, abdominal pain, fever.
  • Note severity: mild, moderate, severe, fulminant.
  • Record treatment: antibiotics, fecal transplant.

Coding and Audit Risks

Common Risks
  • Unspecified C. diff

    Coding C. diff without specifying infection type (e.g., primary, recurrent) leads to inaccurate severity and reimbursement.

  • Missed CDI Present on Admission

    Failing to document C. diff as present on admission (POA) impacts quality reporting and hospital-acquired infection metrics.

  • Lack of Supporting Documentation

    Insufficient documentation of C. diff diagnosis (e.g., lab results, clinical findings) can trigger claim denials and audits.

Mitigation Tips

Best Practices
  • Document C. difficile symptoms, onset, and risk factors for accurate ICD-10 coding (A04.7).
  • Ensure CDI specialists query physicians for clarification on C. difficile diagnosis for compliant billing.
  • Implement infection control measures like hand hygiene and contact precautions to prevent C. difficile transmission.
  • Optimize antibiotic stewardship programs to minimize C. difficile risk and improve patient outcomes.
  • Monitor lab tests for C. difficile toxins A/B and GDH for accurate diagnosis and severity assessment.

Clinical Decision Support

Checklist
  • Recent antibiotic use? Document type and duration.
  • ≥3 loose stools in 24 hours? Document stool characteristics.
  • Consider C. difficile testing. PCR preferred. Document indication.
  • Positive C. difficile test? Assess severity. Document criteria.
  • Initiate appropriate treatment and precautions. Document plan.

Reimbursement and Quality Metrics

Impact Summary
  • C. difficile reimbursement impacted by coding accuracy (ICD-10-CM A04.7), affecting hospital case mix index.
  • C. diff diagnosis quality metrics: Infection prevention, CDI management, antibiotic stewardship programs affect value-based purchasing.
  • Accurate C. difficile coding (A04.7) crucial for proper MS-DRG assignment and appropriate hospital reimbursement.
  • C. difficile infection reporting impacts public health surveillance, influencing hospital-acquired infection reduction strategies.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What are the most recent evidence-based guidelines for diagnosing Clostridium difficile infection (CDI) in adults?

A: Diagnosing Clostridium difficile infection (CDI) requires a multi-faceted approach. Current guidelines, such as those from the IDSA and SHEA, emphasize the importance of considering clinical symptoms like unexplained diarrhea, abdominal pain, and fever, in conjunction with laboratory testing. While nucleic acid amplification tests (NAATs) are highly sensitive, they can detect colonization without active infection. Therefore, it's crucial to combine NAAT results with clinical context and consider other factors like recent antibiotic use, prior CDI history, and presence of inflammatory markers. Over-reliance on NAATs alone can lead to overdiagnosis and unnecessary treatment. For patients with a positive NAAT, evaluating for the presence of toxins A and B can help distinguish between colonization and active infection. Explore how incorporating these guidelines can improve CDI diagnosis accuracy in your practice.

Q: How can I differentiate Clostridium difficile infection from other causes of antibiotic-associated diarrhea in hospitalized patients?

A: Differentiating Clostridium difficile infection (CDI) from other causes of antibiotic-associated diarrhea (AAD) is challenging. While CDI is a frequent culprit, other infectious agents and even the antibiotic itself can trigger AAD. Key differentiators for CDI include the characteristic foul odor of the stool, significant leukocytosis, and the presence of pseudomembranes on colonoscopy. However, not all patients with CDI will exhibit these features. Consider other potential diagnoses like Klebsiella oxytoca, Salmonella, and Campylobacter infection, especially if the patient's symptoms don't fully align with typical CDI presentation. A thorough patient history, including recent antibiotic use, travel history, and dietary habits, can provide valuable clues. Stool cultures and other diagnostic tests may be necessary to rule out alternative diagnoses. Learn more about the latest diagnostic algorithms for distinguishing CDI from other causes of AAD.

Quick Tips

Practical Coding Tips
  • Code C. diff infections with A04.7
  • Document toxin assays & severity
  • Query physician for CDI type
  • Include ICD-10-CM Z22.828
  • Consider CDI-related complications

Documentation Templates

Patient presents with symptoms consistent with Clostridium difficile infection (CDI, C. diff), including frequent watery diarrhea, abdominal pain, and cramping.  Onset of symptoms began approximately [Number] days ago following recent antibiotic use of [Antibiotic Name].  Patient reports [Number] bowel movements per day with a characteristic foul odor.  Physical examination reveals mild to moderate tenderness in the lower abdomen with no rebound tenderness or guarding.  Vital signs are as follows: temperature [Temperature], heart rate [Heart rate], blood pressure [Blood pressure], respiratory rate [Respiratory rate].  Stool studies were ordered for Clostridium difficile toxin and PCR testing.  Differential diagnosis includes antibiotic-associated diarrhea, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).  Given the clinical presentation and recent antibiotic exposure, Clostridium difficile infection is the most likely diagnosis.  Treatment plan includes discontinuation of the current antibiotic, if possible, and initiation of oral metronidazole or vancomycin therapy per current IDSA guidelines.  Patient education provided regarding contact precautions, hygiene practices, and the importance of completing the full course of prescribed medication.  Follow-up appointment scheduled in [Number] days to monitor response to therapy and resolution of symptoms.  ICD-10 code A04.7 will be used for Clostridium difficile colitis.  This diagnosis is relevant for medical billing and coding purposes.  Patient's condition and treatment plan will be closely monitored for complications such as pseudomembranous colitis, toxic megacolon, and sepsis.